id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-D-0242-0002,FDA,FDA-2004-D-0242,"Guidance for Industry; Role of HIV Resistance Testing in Antiretroviral
Drug Development",Other,Guidance,2007-10-30T04:00:00Z,2007,10,2007-10-30T04:00:00Z,,2024-11-12T04:12:49Z,,1,0,09000064804719c3
FDA-2004-D-0242-0001,FDA,FDA-2004-D-0242,FDA,Notice,NAD-Notice of Availability of Data,2004-12-09T05:00:00Z,2004,12,2004-11-29T05:00:00Z,2005-03-01T04:59:59Z,2008-04-12T00:35:21Z,,0,0,09000064804719a3